Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Zhonghong Guan"'
Publikováno v:
Neurourology and Urodynamics. 37:237-243
AIMS We evaluated the effect of Tolterodine extended release (TER) versus placebo on bladder wall thickness (BWT) using transvaginal ultrasound in women with overactive bladder (OAB). MATERIALS AND METHODS We recruited 79 women with symptoms of OAB w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0091c294814ef1227943611cd69de760
https://doi.org/10.1002/nau.23281
https://doi.org/10.1002/nau.23281
Publikováno v:
BJU International. 109:1831-1840
Study Type – Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Male lower urinary tract symptoms are often attributed to bladder outlet obstruction secondary to benign prostatic hyperplasia and treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc156719eb79a7e19984603a9a9634ed
https://doi.org/10.1111/j.1464-410x.2011.10624.x
https://doi.org/10.1111/j.1464-410x.2011.10624.x
Autor:
Alan D. Garely, Jacques Corcos, Zhonghong Guan, Martin Carlsson, Javier C. Angulo, Jason Gong
Publikováno v:
Current Medical Research and Opinion. 27:1059-1065
To assess the onset of efficacy of fesoterodine 4 mg versus placebo in subjects with overactive bladder (OAB) symptoms.Subjects who reported OAB symptoms for ≥ 3 months and recorded ≥ 8 micturitions and ≥ 1 urgency urinary incontinence (UUI) ep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fb9297c76239638923c7939af645e48
https://doi.org/10.1185/03007995.2011.565044
https://doi.org/10.1185/03007995.2011.565044
Autor:
Steven A. Kaplan, Christopher R. Chapple, Tamara Bavendam, Claus G. Roehrborn, Paul Abrams, Zhonghong Guan
Publikováno v:
International Journal of Clinical Practice. 65:487-507
Despite potential benefits, primary care clinicians may avoid using antimuscarinics in men with overactive bladder (OAB) symptoms because of safety concerns. To review the efficacy and safety of antimuscarinics, alone or in combination with an α-blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a31eeb06857a25dc6d0470a1ff6923c
https://doi.org/10.1111/j.1742-1241.2010.02611.x
https://doi.org/10.1111/j.1742-1241.2010.02611.x
Publikováno v:
European Urology. 58:532-543
Context Overactive bladder (OAB) and urinary incontinence (UI) are worldwide public health problems. Longitudinal epidemiologic studies that assess the natural history of OAB and UI are valuable in making accurate prognoses, determining causes and co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a687c8707feccd162286da73d2d272
https://doi.org/10.1016/j.eururo.2010.06.007
https://doi.org/10.1016/j.eururo.2010.06.007
Autor:
Steven A. Kaplan, Martin Carlsson, Jenelle E. Foote, Zhonghong Guan, Jason Gong, Tim Schneider
Publikováno v:
BJU International. 107:1432-1440
Study Type – Therapy (RCT) Level of Evidence 1b What’s known on the subject? and What does the study add? A previous trial found greater efficacy with the maximum available dose of fesoterodine 8 mg compared with the maximum available dose of tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb99704a67dd58ced49010ff8d8b1c79
https://doi.org/10.1111/j.1464-410x.2010.09640.x
https://doi.org/10.1111/j.1464-410x.2010.09640.x
Publikováno v:
BJU International. 106:816-821
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVES To determine whether baseline urgency urinary incontinence (UUI) episodes predict the need for increased doses of fesoterodine in patients with overactive bladder (OAB), as clinicians would
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::960de45fccd1abb784a7785e1ddaa672
https://doi.org/10.1111/j.1464-410x.2010.09202.x
https://doi.org/10.1111/j.1464-410x.2010.09202.x
Autor:
Christopher R. Chapple, Zhonghong Guan, Marina Brodsky, Joseph T. Wang, Paul Abrams, Sender Herschorn
Publikováno v:
BJU International. 106:1332-1338
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE To determine whether the efficacy and safety of a combination of tolterodine extended-release (ER) plus α-blocker treatment varies with high or low levels of serum prostate-specific antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db2aeb9f01922e5ab7310a67c396c3e7
https://doi.org/10.1111/j.1464-410x.2010.09359.x
https://doi.org/10.1111/j.1464-410x.2010.09359.x
Autor:
Zhonghong Guan, J. Stephen Jones, Joseph T. Wang, Matthias Oelke, Scott MacDiarmid, Sender Herschorn
Publikováno v:
Urology. 75:1149-1155
OBJECTIVES To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg in men with overactive bladder. METHODS This was a subanalysis of pooled data from 358 men enrolled in 2 double-blind, placebo-controlled phase III trials. Subject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f5184c481c377ba00b3231e17d1a1db
https://doi.org/10.1016/j.urology.2009.09.007
https://doi.org/10.1016/j.urology.2009.09.007
Autor:
Martin C. Michel, Zhonghong Guan, Jon D. Morrow, David R. Staskin, Joseph T. Wang, Victor W. Nitti
Publikováno v:
Current medical research and opinion, 26(4), 813-818. Taylor and Francis Ltd.
Fesoterodine is an antimuscarinic agent indicated for the treatment of overactive bladder (OAB) symptoms. The objective of this study was to evaluate the efficacy of fesoterodine versus placebo over selected intervals during a 24-hour period in subje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eefb39ee7750d7ffcd89e668251a485
https://doi.org/10.1185/03007990903585707
https://doi.org/10.1185/03007990903585707